No Data
No Data
China Biotech Services Holdings Limited's (HKG:8037) 28% Share Price Surge Not Quite Adding Up
Despite an already strong run, China Biotech Services Holdings Limited (HKG:8037) shares have been powering on, with a gain of 28% in the last thirty days. Unfortunately, the gains of the last
CH Biotech Ser (08037): Xu Haiyin resigns as non-executive director.
Ch Biotech Ser (08037) announced that Ms. Xu Haiyin has resigned as a non-executive director of the company, effective from 202...
Ch Biotech Ser (08037): Guo Yuantao has been appointed as an independent non-executive director.
Ch Biotech Ser (08037) announced that Guo Yuantao has been appointed as an independent non-executive director, as well as a member of the audit committee, nomination committee, and remuneration committee, effective immediately following the annual general meeting of shareholders.
ch biotech ser announced clinical trial results at the American ASCO 2024 annual meeting.
CH Biotech Ser (08037) announced that its indirectly non-wholly-owned subsidiary, Shanghai Longyao Biotechnology Co., Ltd., presented the results of Phase I clinical study on LY007 cell injection (a new autologous chimeric antigen receptor T-cell therapeutic product targeting CD20) for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL) at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) in the form of a poster exhibition. It is reported that diffuse large B-cell lymphoma (DLBCL) (LBC
ch biotech ser (08037) announced the clinical trial results at the 2024 annual meeting of the American Society of Clinical Oncology.
Zhìtōng Cáijīng APP reports that CH Biotech Ser (08037) released an announcement that its indirectly non-wholly owned subsidiary, Shanghai Longyao Biotechnology Co., Ltd., showcased the results of its Phase I clinical trial of LY007 cell injection (a new autologous chimeric antigen receptor T cell therapy product targeting CD20) in patients with relapsed/refractory B cell non-Hodgkin's lymphoma (B-NHL) at the American Society of Clinical Oncology (ASCO) 2024 annual meeting in the form of a poster presentation. It is reported that diffuse large B-cell lymphoma (DLBCL) is one of the most aggressive, heterogeneous, and common subtypes of B-cell NHL, accounting for approximately 40% of cases in China.
China Biotechnology Services (08037) guarantees Shanghai Longyao
China Biotechnology Service (08037) announced that Shanghai Longyao Biotechnology, an indirect non-wholly-owned subsidiary of the company, has...
No Data